sprycel posts
Feed
I'm reiterating my Buy rating for Bristol-Myers Squibb (NYSE: BMY), first recommended on June 1, 2009 at a price of $20.11. 
Readers of this space know that the investment bias is toward large-cap companies with demonstrated business models and who have a competitive advantage in established markets, preferably with a favorable, global trend as a support. And with that in mind, Bristol-Myers Squibb (NYSE: BMY) is worth a review. Continue reading Time to scoop up some shares of Bristol-Myers Squibb
| # | Blogger | Posts | Cmts |
|---|---|---|---|
| 1 | Joseph Lazzaro | 101 | 0 |
| 2 | Tom Johansmeyer | 94 | 3 |
| 3 | Connie Madon | 50 | 0 |
| 4 | Steven Mallas | 42 | 0 |
| 5 | Mark Fightmaster | 39 | 0 |
| 6 | Tom Taulli | 38 | 0 |
| 7 | Steven Halpern | 29 | 0 |
| 8 | Trey Thoelcke | 28 | 0 |
| 9 | Melly Alazraki | 25 | 0 |
| 10 | Paul Foster | 23 | 0 |
| 11 | Zac Bissonnette | 23 | 0 |
| 12 | Jon Ogg | 20 | 0 |
| 13 | Brian White | 20 | 0 |
| 14 | Jim Cramer | 20 | 0 |
| 15 | Brent Archer | 20 | 0 |
| 16 | Eric Buscemi | 17 | 0 |
| 17 | Elizabeth Harrow | 17 | 0 |
| 18 | Sheldon Liber | 13 | 0 |
| 19 | Beth Gaston Moon | 8 | 0 |
| 20 | Michael Fowlkes | 7 | 0 |
Find out why more people track their portfolios on AOL Money & Finance then anywhere else.
Six Thanksgiving trades for tasty profits
Closing Bell: Dubai sends jitters throughout the market (S, BBY)
Heinz looking good after the second quarter?